Clinical use of crizotinib for the treatment of non-small cell lung cancer

Abstract

Discoveries over the last decade have fundamentally transformed the way we define lung cancer. Gone are the days of the simple binary classification system of non-small cell lung cancer (NSCLC) and small cell lung cancer. Today, accurate identification of the histological and molecular subtype of NSCLC is required for selecting standard cytotoxic chemotherapy and targeted therapies. The identification of anaplastic lymphoma kinase (ALK) rearrangements in 5–7% of NSCLC patients and the rapid clinical development of crizotinib for these patients is the most recent clinical example necessitating the proper identification of the molecular characteristics of NSCLC for treatment decisions. The discovery of ALK rearrangements in NSCLC serendipitously coincided with the development of crizotinib for other ALK or MET driven malignancies. The clinical development of crizotinib for ALK-positive NSCLC patients has been an amazing success story of translational medicine that relied on the prior clinical experience of other targeted predecessors (i.e. erlotinib in EGFR mutant NSCLC) and a compound ready for clinical development to gain expedited FDA approval. This review discusses the clinical development and use of crizotinib in NSCLC.

Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology

“…70,204 Crizotinib is also recommended for patients who are positive for ROS1 rearrangements and MET amplification. 115,116,205,206 For the 2017 update (Version 1), the NCCN panel added a recommendation for testing for ROS1 rearrangements (category 2A). Testing for ROS1 has typically been performed using FISH; however, a validated NGS platform that can detect this gene fusion may also be used.…”

Text mining‑based drug discovery in cutaneous squamous cell carcinoma

“…TKIs that work by blocking the Bcr-Abl tyrosine-kinase included dasatinib, imatinib, bosutinib and ponatinib, which have been used to treat chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), Philadelphia chromosome-positive (Ph + ) (26). ALK inhibitors, crizotinib and ceritinib, were approved for the treatment of some NSCLC cases in the US and other countries, but have not been formally evaluated in the setting of cSCC (27). Other drugs such as masitinib, sorafenib and sunitinib inhibit cellular signaling by targeting multiple RTKs, including platelet-derived growth factor (PDGFR), vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and RAF family kinases, which play an important role in both tumor angiogenesis and tumor cell proliferation (28)(29)(30).…”

On-Line Sequential Chemiluminescence Detection of the Chemotherapy Crizotinib With Luminol-Potassium Ferricyanide/Silver Nanoparticles System in Pharmaceutical Preparations and Human Serum

“…It acts as an anaplastic lymphoma kinase inhibitor and recommended for the treatment of lung carcinoma. [1] It is mainly used in patients having large cell lung cancer. Recently, its binary medication with dasatinib may be evaluated to be used for the treatment of high grade glioma.…”